Disclaimer: This is a machine generated PDF of selected content from our products. This functionality is provided solely for yourconvenience and is in no way intended to replace original scanned PDF. Neither Cengage Learning nor its licensors make anyrepresentations or warranties with respect to the machine generated PDF. The PDF is automatically generated "AS IS" and "ASAVAILABLE" and are not retained in our systems. CENGAGE LEARNING AND ITS LICENSORS SPECIFICALLY DISCLAIM ANYAND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY,ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULARPURPOSE. Your use of the machine generated PDF is subject to all use restrictions contained in The Cengage LearningSubscription and License Agreement and/or the Gale Power Search Terms and Conditions and by using the machine generatedPDF functionality you agree to forgo any and all claims against Cengage Learning or its licensors for your use of the machinegenerated PDF functionality and any output derived therefrom.
Findings from Netherlands Cancer Institute in Breast CancerReported (High-dose chemotherapy with stem cell rescue totreat stage III homologous deficient breast cancer: factorsinfluencing clinical implementation).Date: Jan. 26, 2023 From: Women's Health WeeklyPublisher: NewsRX LLCDocument Type: Article Length: 495 words
Full Text: 2023 JAN 26 (NewsRx) — By a News Reporter-Staff News Editor at Women's Health Weekly — Researchers detail new data in breastcancer. According to news originating from the Netherlands Cancer Institute by NewsRx correspondents, research stated, "High-dosechemotherapy with autologous stem cell rescue (HDCT) is a promising treatment for patients with stage III, HER2-negative,homologous recombination deficient (HRD) breast cancer. Clinical effectiveness and cost-effectiveness are currently underinvestigation in an international multicenter randomized controlled trial."
Financial supporters for this research include Kwf Kankerbestrijding; Zonmw.
Our news reporters obtained a quote from the research from Netherlands Cancer Institute: "To increase the chance of successfulintroduction of HDCT into daily clinical practice, we aimed to identify relevant factors for smooth implementation using an earlycomprehensive assessment framework. This is a qualitative, multi-stakeholder, exploratory research using semi-structured interviewsguided by the Constructive Technology Assessment model, which evaluates the quality of a novel health technology by clinical,economic, patient-related, and organizational factors. Stakeholders were recruited by purposeful stratified sampling and intervieweduntil sufficient content saturation was reached. Two researchers independently created themes, categories, and subcategories byfollowing inductive coding steps, these were verified by a third researcher. We interviewed 28 stakeholders between June 2019 andApril 2021. In total, five overarching themes and seventeen categories were identified. Important findings for optimal implementationincluded the structural identification and referral of all eligible patients, early integration of supportive care, multidisciplinarycollaboration between- and within hospitals, (de)centralization of treatment aspects, the provision of information for patients andhealthcare professionals, and compliance to new regulation for the BRCA1-like test."
According to the news editors, the research concluded: "In anticipation of a positive reimbursement decision, we recommend to takethe highlighted implementation factors into consideration. This might expedite and guide high-quality equitable access to HDCT forpatients with stage III, HER2-negative, HRD breast cancer in the Netherlands."
For more information on this research see: High-dose chemotherapy with stem cell rescue to treat stage III homologous deficientbreast cancer: factors influencing clinical implementation. BMC Cancer, 2023,23(1):1-11. (BMC Cancer -http://bmccancer.biomedcentral.com). The publisher for BMC Cancer is BMC.
A free version of this journal article is available at https://doi.org/10.1186/s12885-022-10412-x.
Our news journalists report that more information may be obtained by contacting Joost G. E. Verbeek, Division of PsychosocialResearch and Epidemiology, Netherlands Cancer Institute. Additional authors for this research include Vincent M. T. de Jong, HannaM. Wijnja, Agnes Jager, Sabine C. Linn, Valesca P. Retel, Wim H. van Harten.
Keywords for this news article include: Netherlands Cancer Institute, Oncology, Technology, Chemotherapy, Breast Cancer,Women's Health, Stem Cell Research, Drugs and Therapies, Health and Medicine.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2023, NewsRx LLC
The citation for this news report is: NewsRx. Findings from Netherlands Cancer Institute in Breast Cancer Reported (High-dosechemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation).Women's Health Weekly. January 26, 2023; p 2024.
Copyright: COPYRIGHT 2023 NewsRX LLC http://www.newsrx.com/newsletters/Womens-Health-Weekly.htmlSource Citation (MLA 9th Edition) "Findings from Netherlands Cancer Institute in Breast Cancer Reported (High-dose chemotherapy with stem cell rescue to treat stage
III homologous deficient breast cancer: factors influencing clinical implementation)." Women's Health Weekly, 26 Jan. 2023, p.2024. Gale OneFile: Business, link.gale.com/apps/doc/A734154513/GPS?u=lirn50909&sid=bookmark-GPS&xid=36a3295f.Accessed 7 Feb. 2023.
Gale Document Number: GALE|A734154513